Marker Therapeutics Inc (MRKR)

[hanscott]

Re. Questions on IP.

Does anyone here remember discussing this lovely lady's efforts using Multi-TAA T-Cells a year or three ago? Catherine Bollard, M.D., MBChB. I don't recall what became of the discussion.

She's a cofounder of MANA Theraputics. They are a private company.

They raised $50mil from 6 investors on Nov 30, 2021, which is right around the time when MRKR dropped to ~$1.

It looks like we are well ahead of them in in terms of clinical trials if you include the Baylor trials. But still, it does bring up the IP question and complicates things a bit.


1. Their approach is similar to ours, except they are are using one less antigen than MRKR, and they are producing T-Cells for "off the shelf" delivery: they collect and produce T cells from donors in advance and freeze them.

Their antigen mix: WT1, PRAME, and SURVIVIN.
Our Antigen Mix: WT1, PRAME, Survivin, NY-ESO-1

2. They have a similar AML P1 clinical Trial in progress, with one publication

3. In 2020, they improved their T Cell production to produce doses up to 200 million T cells. Our current P2 AML study is using is using 50 million T cells.

4. On their "Our Story" page it says, " MANA is also in discussions with multiple partners who have proprietary antigens to permit development of partnered MANA products for a broad range of cancer indications."

------------------------
edit: It will be interesting to see what changes have occurred in Institutional Investors in MRKR with the next update. There were ~15mil shares traded during last week's drop in price after the Orphan Drug Designation . . .